Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

Core Viewpoint - Tianjin Jiuan Medical Electronics Co., Ltd. has recently acquired a piece of industrial land in Nankai District, marking it as the fourth industrial land transaction in the area since 2025, following companies like Jiuzhoutong Pharmaceutical Group and Aier Eye Hospital Group [1] Group 1: Industrial Land Development - Nankai District is focusing on simultaneous promotion of investment attraction and revitalization of idle assets, aiming to gather the development of science and technology innovation industries [1] - The district's strategy includes optimizing spatial layout into a "one core, two axes, three zones" structure, with the Tiankai Higher Education Science and Technology Innovation Park as the innovation engine [1] Group 2: Modern Industrial System - Nankai District has proposed a "3+2" modern urban industrial system, emphasizing three main industries: technology services, intelligent manufacturing, and biomedicine, along with two characteristic industries: cultural tourism and commercial services [2] - The technology service sector will leverage resources from universities and key laboratories to create a comprehensive service system covering R&D, technology transfer, concept validation, intellectual property, and technology finance [2]

Group 1 - Tianjin Jiuan Medical Electronics Co., Ltd. has recently acquired an industrial land in Nankai District, marking it as the fourth industrial land transaction in the area since 2025, following companies like Jiuzhoutong Pharmaceutical Group and Aier Eye Hospital Group [1] - Nankai District is focusing on synchronizing investment attraction and revitalization efforts to enhance the development of the science and technology innovation industry [1] - The district aims to optimize its spatial layout into a structure of "one core, two axes, and three zones," with the Tiankai Higher Education Science and Technology Innovation Park as the innovation engine [1] Group 2 - Nankai District has proposed to develop a "3+2" modern urban industrial system, focusing on three main industries: technology services, intelligent manufacturing, and biomedicine, along with two characteristic industries: cultural tourism and commercial services [2] - The district plans to accelerate the transformation of old and new driving forces by strengthening its leading industries and nurturing future industries [2] - The technology service industry will leverage resources from universities and key laboratories to create a comprehensive service system covering research and development, technology transfer, concept validation, intellectual property, and technology finance [2]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Group 1 - The strategic cooperation signing ceremony took place between Lunan Pharmaceutical Group and Jiuzhoutong Pharmaceutical Group Hubei Company on January 8 [1] - Jiuzhoutong emphasized its commitment to establishing long-term, stable, and win-win relationships with excellent partners, highlighting the complementary strengths of Lunan's innovative concepts and product capabilities with Jiuzhoutong's channel network and service advantages [3] - The "Changying Plan" aims to enhance collaboration in digital supply chains and terminal service innovations, reinforcing strategic trust and addressing industry changes to contribute to the health of the Chinese population [3] Group 2 - Lunan Pharmaceutical Group presented its core product "Qidali" based on the philosophy of "Zhongzheng Pinghe," discussing its practices and reflections [3] - The essence of the "Changying Plan" is to adhere to long-termism, build a development community, and improve the overall efficiency and resilience of the industry chain through resource sharing and complementary advantages [3] - Both companies aspire to achieve sustained commercial success while creating greater value for public health and fostering a new model of value co-creation and sustainable win-win outcomes [3]

Core Viewpoint - Zhejiang Kailesi Technology Group Co., Ltd. (Kailesi) is preparing for its IPO on the Hong Kong Stock Exchange, aiming to become the first stock in the field of all-stack intelligent in-house logistics robots in Hong Kong [3]. Company Overview - Founded in 2014 by Gu Chunguang and Yang Yan, both Tsinghua University graduates, Kailesi has become the fifth largest comprehensive intelligent in-house logistics solution provider in China, with a market share of 1.6% [4]. - The company leads the market in the ultra-narrow aisle autonomous mobile robot (VNA AMR) segment with a shipment market share of 19.3% [4]. Financial Performance - Kailesi's revenue for 2024 is projected to reach 721 million RMB, a year-on-year increase of 30.8%, while the revenue for the first nine months of 2025 has already reached 552 million RMB, reflecting a growth of 60.3% [5]. - As of the end of 2024, the company has completed 1,530 projects and served 779 clients across 28 industries, including new energy, automotive, pharmaceuticals, and e-commerce, with operations in 16 countries and regions [5]. Investment and Shareholding - The company has completed multiple rounds of financing totaling over 800 million RMB, with a valuation of 3.5 billion RMB after the E round in 2022 [6]. - Founders Gu Chunguang and Yang Yan hold approximately 40.3% of the shares, while major shareholders include SF Holding (14.1%) and CICC Capital (10.15%) [6]. Product and Technology - Kailesi's core philosophy is "scene-oriented, technology-based," and it offers a product line that includes four-way shuttle robots (MSR), autonomous mobile robots (AMR), and sorting robots, along with a full-stack software system [22]. - The four-way shuttle technology enhances warehouse space utilization by over 50% and reduces energy consumption by 30% compared to traditional systems [24]. Market Expansion - Kailesi has expanded its market presence from pharmaceuticals to e-commerce, automotive, and now into higher barrier and faster-growing sectors like new energy and semiconductors [28]. - The company has initiated its international expansion with projects in Russia and plans to target Southeast Asia, Japan, South Korea, the Middle East, Europe, and North America [29]. Competitive Landscape - The logistics robot sector in China is experiencing rapid growth, with an expected market size of 413.7 billion RMB by 2030, attracting nearly 400 competitors [36]. - Key competitors include companies like Geek+, Hikvision Robotics, and FastGo Intelligent, with a shift in focus from hardware competition to ecosystem building [40].

重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年1月7日 (二)股东会召开的地点：武汉市汉阳区龙兴西街5号九州通总部大厦会议室 证券代码：600998 证券简称：九州通 公告编号：临2026-004 九州通医药集团股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式进行表决，经推举，会议由副董 事长刘兆年先生主持。会议召集、召开和表决程序符合《公司法》及《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事14人，列席14人； 2、公司董事会秘书出席了本次会议；部分高级管理人员列席了本次会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于2026年度公司及下属企业申请银行等机构综合授信 ...

证券日报网讯 1月7日，九州通发布公告称，公司2026年第一次临时股东会审议通过《关于2026年度公 司及下属企业申请银行等机构综合授信计划的议案》《关于2026年度公司及下属企业办理银行等机构综 合授信及其他业务提供担保的议案》《关于公司2026年度使用临时闲置资金委托理财预计的议案》等多 项议案。 （文章来源：证券日报） ...

证券代码：600998 证券简称：九州通 公告编号：临 2026-004 九州通医药集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 440 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 3,248,677,924 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 65.1503 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式进行 表决，经推举，会议由副董事长刘兆年先生主持。会议召集、召开和表决程序符 (一) 股东会召开的时间：2026 年 1 月 7 日 (二) 股东会召开的地点：武汉市汉阳区龙兴西街 5 号九州通总部大厦会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 合《公司法》及《公司 ...

北京市朝阳区建外大街甲 14 号广播大厦 5/9/10/13/17 层 北京海润天睿律师事务所 关于九州通医药集团股份有限公司 2026 年第一次临时股东会的法律意见书 致：九州通医药集团股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受九州通医药集团股份 有限公司（以下简称"公司"）的委托，指派本所律师出席公司 2026 年第一次 临时股东会（以下简称"本次股东会"），并依据《中华人民共和国公司法》（以 下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规则》）、 《公司章程》及其他相关法律、法规的规定，就公司本次股东会的召集、召开程 序、出席会议人员的资格、召集人资格、表决程序及表决结果等有关事宜出具本 法律意见书。 对本法律意见书的出具，本所律师特作如下声明：本所及经办律师依据《证 券法》《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务 执业规则》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履 行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证 本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误 ...